Hypoperfusion Intensity Ratio Correlates with CTA Collateral Status in Large-Vessel Occlusion Acute Ischemic Stroke

D Lyndon1,2, M van den Broek1,2, B Niu3

  • 1Neuroradiology Division (D.L., M.v.d.B., A.R., F.S.), Vancouver General Hospital, Vancouver, British Columbia, Canada.

Insights

The hypoperfusion intensity ratio, an automated CTP measure, accurately reflects collateral status in large-vessel occlusion stroke, offering a quantitative alternative to subjective CTA scoring for improved stroke assessment.

Area of Science:

  • Neurology
  • Radiology
  • Medical Imaging

Background:

  • Collateral blood supply is crucial for outcomes in large-vessel occlusion acute ischemic stroke.
  • Current collateral scoring systems using CT angiography (CTA) are subjective and require specialized training.

Purpose of the Study:

  • To evaluate the association between the CTP-derived hypoperfusion intensity ratio and CTA collateral status.
  • To determine if a hypoperfusion intensity ratio threshold can predict poor CTA collaterals.

Main Methods:

  • Retrospective review of imaging and clinical data from 52 patients with large-vessel occlusion acute ischemic stroke.
  • Collateral scoring using single-phase and multiphase CTA (Tan, Maas, Calgary/Menon methods).
  • CT perfusion (CTP) analysis using RAPID software to calculate the hypoperfusion intensity ratio.

Main Results:

  • Multiphase CTA scoring demonstrated superior interrater agreement (κ = 0.813) compared to single-phase CTA.
  • The hypoperfusion intensity ratio showed a significant correlation with multiphase CTA collateral scores (r = -0.55, P ≤ .001).
  • A hypoperfusion intensity ratio threshold of >0.45 effectively predicted poor multiphase CTA collateral status (AUC = 0.86).

Conclusions:

  • The hypoperfusion intensity ratio is a reliable, automated, and quantitative measure associated with CTA collateral status in large-vessel occlusion stroke.
  • This CTP-derived ratio serves as a valuable alternative to subjective CTA collateral scoring in clinical practice and stroke trials.
Abstract